Deelip Chatterjee, MD
Pulmonary Disease · West Paterson, NJNPI 1790894707
Payments from drug & device makers
Across 244 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$295
- Amgen$171
- Actelion Pharmaceuticals US, Inc.$159
- Pfizer$116
- plus $885 from 21 others
What the payments were for
- Food & beverage$4,25198%
- Education$782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 96 | $1,635 |
| AstraZeneca(2 entities) | 42 | $1,068 |
| Boehringer Ingelheim | 22 | $295 |
| Amgen(2 entities) | 12 | $171 |
| Actelion Pharmaceuticals US, Inc. | 9 | $159 |
| Pfizer | 6 | $116 |
| Radius Health, Inc. | 7 | $106 |
| Insmed, Inc. | 6 | $103 |
| Harmony Biosciences LLC | 6 | $82 |
| Lilly USA, LLC | 4 | $57 |
| Johnson & Johnson(2 entities) | 3 | $52 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $52 |
| Philips North America LLC | 4 | $51 |
| Sanofi | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Viatris Specialty LLC | 2 | $38 |
| Fresenius Kabi USA, LLC | 2 | $34 |
| Novo Nordisk | 2 | $31 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Exact Sciences | 1 | $24 |
| 3b Medical, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$473
- ANORO$236
- ANORO ELLIPTA$125
How this compares
$4,329 in reported general payments places this provider in the 60th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 96 | $112,472 |
| XolairOmalizumab | 24 | $85,817 |
| OzempicSemaglutide | 65 | $62,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $46,265 |
| EliquisApixaban | 51 | $29,766 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $27,648 |
| LinzessLinaclotide | 47 | $23,463 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $19,343 |
| JanuviaSitagliptin Phosphate | 29 | $16,894 |
| MounjaroTirzepatide | 15 | $15,495 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $12,645 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 310 | $8,169 |
| ErtapenemErtapenem Sodium | 19 | $7,989 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,303 |
| Varenicline Tartrate | 19 | $5,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $57 | $127,968111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,635 | $65,608109 claims |
| Novo NordiskOzempic | $31 | $62,31165 claims |
| PfizerEliquis | $116 | $29,76651 claims |
| AstraZenecaBreztri Aerosphere | $1,068 | $27,64847 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $295 | $17,94833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in West Paterson
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.